Key Highlights

  • Harrow, Inc. (NASDAQ:HROW) finished Tuesday, November 10, 2026 at USD 31.83, a rise of 15.85% from a calculated previous close of USD 27.48, or USD 4.35 per share, in a published screener snapshot of 4,625 names.
  • Revenue for the third quarter reached USD 99.3 million, a 39% increase on USD 71.6 million, with branded Revenue of USD 83.5 million (up 62%), Gross Profit of USD 74.9 million and Net Income of USD 9.8 million, equal to USD 0.25 per diluted share.
  • The company kept its full-year revenue outlook of USD 350 million to USD 365 million, yet trimmed adjusted EBITDA guidance to above USD 40 million, versus the earlier USD 80 million to USD 100 million.
  • Trading Volume was 845.9K shares at a relative volume of 1.35, and the snapshot lists a Market Value of USD 1.19 billion, no P/E and a Dividend Yield of 0.00%.

What Moved Harrow on November 10 (+15.85%)

Harrow closed the regular session at USD 31.83. Basic arithmetic on the snapshot row points to a calculated previous close of USD 27.48 on Monday, November 9, 2026, which sat just 1.9% above the 52-week low of USD 26.96, calculated. The company issued its third quarter results at 4:02 p.m. ET on November 9, and management held its call at 8:00 a.m. ET on November 10. Quarterly revenue of USD 99.3 million was 41% higher than the second quarter. VEVYE contributed USD 39.7 million, up 75%, IHEEZO added USD 25.3 million, up 15%, and TRIESENCE posted a record USD 10.7 million. Net income swung from a USD 17.3 million loss a quarter earlier, while adjusted EBITDA of USD 21.2 million replaced a USD 1.2 million loss.

The Rationale: Third Quarter Results and Lower EBITDA Guidance

The catalyst identified here is the Earnings release. A strong recovery after a soft second quarter, including a USD 5.0 million litigation gain within net income, probably attracted buyers despite the reduced full-year adjusted EBITDA outlook, which implies above USD 33 million for the fourth quarter. Harrow closed the TYRVAYA Acquisition on October 1, 2026 and rolled out HarrowRx on November 1, 2026. In the IHEEZO QUELL study, the non-inferiority endpoint was not met, at 55.2% against 59.7%, although adverse events came in at 27% versus 47%. For general context, a stock can climb when results clear a low expectation, and covering of short positions can amplify a rally. These are mechanisms, not confirmed causes.

Valuation, Liquidity and Risks for Harrow

At USD 31.83, the market value of USD 1.19 billion rests on roughly 37.49 million shares, calculated, and the price stands 42.0% under the 52-week high of USD 54.85 while 18.1% over the low, calculated. The snapshot carries no P/E or usable EPS. Volume of 845.9K shares and a relative volume of 1.35 point to a typical day near 626.6K shares and about USD 26.9 million changing hands, calculated. As of September 30, 2026, cash stood at USD 75.3 million, compared with notes payable of USD 292.7 million and Equity of USD 28.8 million, and Operating Cash Flow over nine months was negative USD 27.4 million, so Debt load is a real risk. One published summary shows a nine-analyst target of USD 63.00, which is a third-party opinion. One strong day says little about later sessions, and nothing here suggests the advance will persist.

Where Things Stand

Harrow, Inc. (NASDAQ:HROW) advanced 15.85% to USD 31.83 on November 10, 2026, probably because record third quarter revenue of USD 99.3 million and a return to profit outweighed the lower adjusted EBITDA outlook. Notes of USD 292.7 million, negative nine-month cash flow and a price 42.0% below the 52-week high moderate the picture, and trading ran at 1.35 times the usual volume.